青岛力腾医药科技

Liteng Pharma is a clinical-stage biopharmaceutical company based in Qingdao, China, specializing in the discovery and development of innovative small molecule therapeutics. Founded in 2017, the company focuses on addressing significant unmet medical needs in the fields of metabolic diseases and autoimmune disorders. Its lead candidate, LT-002, is a potent and selective URAT1 inhibitor currently being evaluated in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Additionally, Liteng Pharma is developing LT-001, a selective JAK1 inhibitor targeting various inflammatory conditions such as atopic dermatitis. The company leverages its internal R&D capabilities to advance a pipeline of candidates from discovery through clinical validation, aiming to provide effective treatments for chronic diseases.